Archive


European Society for Immunodeficiencies (ESID) Bridge Grant

Published by European Society for Immunodeficiencies

GrantPrimary Immunodeficiency

ESID wants to invest in the future of researchers and clinicians committed to PIDs. Therefore ESID Bridge Grants aim to allow trainees working on PIDs to continue their activity in the field of PID in their institution or another institution during short periods of time until they can find other financial sources, thus avoiding the interruption of their training process.

View this resource Bookmark this resource

Research Grants for Angelman Syndrome

Published by Angelman Syndrome Foundation

GrantAngelman Syndrome

The ASF Scientific Advisory Committee identified the following areas of unmet need in AS research. Priority will be given to the following topics:

Projects studying or correcting the heterozygous effect of non-UBE3A genes in deletion.
Projects studying the potential results of increasing UBE3A after therapies or for some subtypes of AS.
Projects studying delivery of therapies and potential for improvement.
Symptomatic therapies that impact the daily life of people with Angelman syndrome and their families.
Proposals that do not address these topics are still welcome and will be given full consideration.

View this resource Bookmark this resource

Development of new effective therapies for rare diseases

Published by European Commission (EC)

Rare DiseaseGrant

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to some of the following expected outcomes:

Researchers and developers make the best use of the state-of-the-art knowledge and resources for a fast and effective development of new therapies for rare diseases.
Researchers and developers increase the development success rate of therapies for rare diseases by employing robust preclinical models, methods, technologies, validated biomarkers, reliable patient reported outcomes and/or innovative clinical trials designs.
Developers and regulators move faster towards market approval of new therapies for rare diseases (with currently no approved treatment option) due to an increased number of interventions successfully tested in late stages of clinical development.
Healthcare professionals and people living with a rare disease get access to new therapeutic interventions and/or orphan medicinal products.

View this resource Bookmark this resource